Michael Gallo

Michael Gallo is currently the President of Innovative Targeting Solutions. Prior to this, he was part of the original scientific team at Cell Genesys that created XenoMouse, the premier transgenic mouse technology for generating fully human antibodies, and spun-off from Cell Genesys in 1996 to start Abgenix. Michael served on the Strategic Planning and Intellectual Property Group at Abgenix and was the Vice President of Research. Abgenix became Amgen British Columbia, and there Michael oversaw over 100 target collaborations including AstraZeneca, Pfizer, Abbot, Curagen, Milleneum, and Dendreon. As the site-head for both Abgenix’s subsidiary (Abgenix Biopharma) and Amgen’s subsidiary (Amgen British Columbia) from 2001 to 2007 he led a research unit of 65 people focused on antibody generation and the development of improved antibody discovery technologies. Michael is an inventor on numerous patents including the commercial antibody Vectibix.

Michael holds a Ph.D. from Ohio State University in the Department of Medical Microbiology and Immunology and completed his post-doctoral studies at Stanford University.